{
    "nct_id": "NCT03107416",
    "official_title": "Phase I/II Study of Transarterial Hepatic Embolization With Bumetanide in Unresectable Hepatocellular Carcinoma",
    "inclusion_criteria": "* Patients with diagnoses of HCC according to European Association for the Study of Liver disease (EASL) criteria for diagnosis (See Appendix 1). Regional lymphadenopathy will be allowed.\n\n  * Any virus status accepted (e.g. Hepatitis C etc.)\n  * Any prior liver treatment\n* Patients within unresectable HCC\n* At least 18 years old\n* ECOG performance status 0 or 1\n* Radiographically measurable disease per mRECIST 1.1\n* Meets standard of care to undergo embolization\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Women who are pregnant or lactating\n* Documented hypersensitivity to bumetanide or sulfonamides\n* Patients with resectable HCC\n* High risk for post-embolization hepatic failure:\n\n  °Child's C cirrhosis\n\n  °> 80% liver involvement by tumor\n* Contraindication to angiography/embolization including:\n\n  * Patients cannot receive contrast:\n  * Severe allergic reaction to contrast despite premedication\n  * Poor renal function not on dialysis\n  * Other, based on judgment of the investigator\n* ECOG score 2\n* Main portal vein tumor thrombus\n* BCLC D = patients with distant metastasis",
    "miscellaneous_criteria": ""
}